[Driving competency after combined treatment with methylprednisolone and orbital radiotherapy for endocrine orbitopathy].
OBJECTIVE
Graves' orbitopathy (GO) in its moderate to severe expression is a disfiguring and disabling disease that profoundly influences activities of daily living. Intravenous steroids and orbital radiotherapy are effective treatments for moderate to severe active GO. We examined the ophthalmological outcomes regarding daily life activities, such as driving competency.


METHODS
In a retrospective case series, we evaluated the data for 21 consecutive patients with moderate to severe and active GO (14 women and seven men) treated with combined orbital radiotherapy (13 Gy) and intravenous methylprednisolone (500 mg weekly for 6 consecutive weeks and 250 mg weekly for consecutive 6 weeks).


RESULTS
The pretreatment mean clinical activity score of 5.2 points (SD ± 0.9) decreased significantly to 2.7 points (SD ± 1.1) in the 12-month follow-up. Analysis of all ocular symptoms showed significant changes for four parameters with different time frames. Inflammatory eye signs--e.g., pain and pressure sensation, caruncle inflammation, and eyelid swelling, including exophthalmos--improved significantly within the first 3 months. Eyelid swelling was significantly reduced 6-12 months after therapy. However, there was no significant improvement of eye motility. Despite anti-inflammatory treatment, 11 patients (52.3%) were not fit to drive a car under binocular conditions. In eight of these patients, additional strabismologic therapy, including prisms or strabismus surgery, was successful.


CONCLUSIONS
The combined therapy of intravenous corticosteroids and orbital radiotherapy reduced inflammatory ophthalmological signs in different time frames. In most cases, strabismologic intervention, including eye muscle surgery, was necessary to restore driving competency.
Sterker
I
I
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Leipzig, Liebigstr. 10-14, 04103, Leipzig, Deutschland, ina.sterker@medizin.uni-leipzig.de.
Tegetmeyer
H
H
Papsdorf
K
K
Führer
D
D
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001333:Automobile Driver Examination; D001334:Automobile Driving; D059248:Chemoradiotherapy / Q000379:methods; D004608:Eligibility Determination; D005858:Germany; D049970:Graves Ophthalmopathy / Q000150:complications / Q000628:therapy*; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D020266:Radiotherapy, Conformal; D016896:Treatment Outcome; D014786:Vision Disorders / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control*; D014792:Visual Acuity
D000893:Anti-Inflammatory Agents; D008775:Methylprednisolone
Lancet. 2000 Apr 29;355(9214):1505-9
10801172
J Clin Endocrinol Metab. 2004 Jan;89(1):15-20
14715820
Thyroid. 2004 May;14(5):403-6
15186621
Endocr Rev. 2000 Apr;21(2):168-99
10782363
Thyroid. 2002 Oct;12(10):855-60
12487767
Eur J Endocrinol. 2002 Apr;146(4):457-61
11916611
J Clin Endocrinol Metab. 2005 Sep;90(9):5234-40
15998777
Thyroid. 2000 Jun;10(6):521
10907999
N Engl J Med. 1998 Jan 8;338(2):73-8
9420337
Endocrinol Metab Clin North Am. 1987 Jun;16(2):391-407
3319588
Eur J Endocrinol. 2008 Mar;158(3):273-85
18299459
J Clin Endocrinol Metab. 2001 Aug;86(8):3562-7
11502779